Home > News > Doping Control >

BIO endorses 'Declaration against Doping in Sport'

2011-06-29 09:59 WADA

June 28, 2011 - The ‘Joint Declaration on Cooperation in the Fight against Doping in Sport’ between the World Anti-Doping Agency (WADA) and the International Federation of Pharmaceutical Manufactures and Associations (IFPMA) has been endorsed by the Biotechnology Industry Organization (BIO).

A resolution to endorse the declaration, which was signed last year, was approved during the BIO International Conference in Washington DC, which runs from June 27-30.

The declaration between WADA and the IFPMA outlined a voluntary cooperation to identify medical compounds with doping potential, restrict misuse of medicines still in development, improve the flow of relevant information, and facilitate development of detection methods in the context of the fight against doping sport.

“This endorsement adds credence to the declaration between WADA and the IFPMA and is further evidence that the fight against doping in sport is becoming more unified,” said WADA President John Fahey.

“It is not only sport that is cheated by the misuse of medicines, the manufacturers are also being cheated, and WADA is delighted with the growing spirit of cooperation in the fight against doping sport.”

As part of their endorsement, BIO will encourage its member organizations to collaborate with WADA and the IFPMA as outlined in the declaration.

“It is of high importance to BIO members that their medicines are used for what they were intended – to save lives and improve the quality of life of patients suffering from serious disease,” said BIO President and CEO Jim Greenwood.

“Our members have continually demonstrated their commitment to the anti-doping cause. Our endorsement of this joint declaration is a natural step in this long-standing tradition and enables us to further reach the goal of eradicating doping in sports.”

A BIO Convention discussion entitled ‘How Dare they Dope with our Medicines’ on Thursday, June 30 will address the issue of anti-doping in sport.

The discussion will be led by Steve Elliott, Scientific Executive Director for Amgen, and will include contributions from Pauline Williams, head of GlaxoSmithKline’s academic discovery performance unit, Barbara Leishman, Clinical Science Leader at Roche, and WADA Director of Science Olivier Rabin. 


About BIO

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations.

BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

Related Story